Enanta Pharmaceuticals, Inc.
↗Watertown, Massachusetts, USA
Enanta Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 1995 that discovers and develops oral small molecule drugs with an emphasis on indications in virology and immunology. The company has established a track record of discovery and development excellence, with its protease inhibitors contributing to over one million hepatitis C virus (HCV) cures through partnerships with AbbVie. Enanta maintains a chemistry-driven approach to drug discovery and is advancing a diversified pipeline focused on respiratory syncytial virus (RSV), immunology, and other infectious disease indications.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Small Molecule Drug Discovery & Development
SIZE & FINANCIALS
Employees:51-200
Revenue:$65.3M annually (FY2025, primarily from MAVYRET royalties)
Founded:1995
Ownership:public
Status:operating
FUNDING
Stage:Public Company
Total Raised:$191M (historical private funding)
Investors:Oxford Bioscience Partners, Advent International, Techno Venture Management
STOCK
Exchange:NASDAQ
Ticker:ENTA
Market Cap:$370-490M (varies by source, as of March 2026)
PIPELINE
Stage:Phase 1-2 clinical
Lead Drug Stage:Phase 2b/3 enabling (zelicapavir for RSV)
Modalities:Small molecule inhibitors, Oral direct-acting antivirals, Protease inhibitors, N-protein inhibitors, L-protein inhibitors, Core inhibitors
Active Trials:3
Trial Phases:Phase 1: 1 | Phase 2: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:AbbVie Inc. (HCV: MAVYRET/MAVIRET, VIEKIRA PAK - ongoing royalties), National Institute of Allergy and Infectious Diseases (NIAID), Novartis, Shionogi Inc.
COMPETITION
Position:Emerging
Competitors:Regeneron Pharmaceuticals, Moderna, Vertex Pharmaceuticals, Gilead Sciences, Roche, Ironwood Pharmaceuticals, Arrakis Therapeutics, KalVista Pharmaceuticals +2 more
LEADERSHIP
Key Executives:
Jay R. Luly, Ph.D. - President & CEO, Director
Bruce L.A. Carter, Ph.D. - Chairman of the Board
Tara L. Kieffer, Ph.D. - Chief Product Strategy Officer
Kristine Peterson - Board Member
Terry Vance - Board Member
Mark G. Foletta - Board Member
Yujiro S. Hata - Board Member
Board Members:Bruce L.A. Carter, Ph.D. (Chairman), Jay R. Luly, Ph.D. (CEO), Kristine Peterson, Terry Vance, Mark G. Foletta, Yujiro S. Hata
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Enanta Pharmaceuticals, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Enanta Pharmaceuticals, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.